SLC5A2 and type 2 diabetes mellitus: Simon and collaborators were the first authors to retrospectively compare the effects of GLP-1RAs and DPP4 inhibitors, sulfonylureas, or SGLT-2 inhibitors on the risk of hepatic decompensation events (the composite of hospitalizations due to ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, bleeding esophageal varices, or hepatic encephalopathy) in patients with T2DM and cirrhosis [54].